Navigation Links
Bionovo to Present at Merriman Curhan Ford's Investor Summit 2008 on September 15th
Date:9/12/2008

EMERYVILLE, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women's health and cancer, announced today that Dr. Isaac Cohen, Chairman and CEO, and Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo, will be presenting at the Merriman Curhan Ford's 5th annual Investor Summit on September 15, 2008 at 2:15 p.m. This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco.

The presentation will be webcast and can be viewed via Bionovo's website at http://webcasts.bionovo.com. A webcast replay will become available shortly after the presentation ends and will continue to be accessible for 90 days via Bionovo's website.

More information about the conference can be found at: http://mcfco.com/AboutUs/Conferences_YearBook.php?ConferenceName=InvestorSu mmi t2008

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.

About Merriman Curhan Ford

Merriman Curhan Ford Group, Inc. is a financial services firm focused on fast-growing companies and the institutions who invest in them. The company offers high-quality investment banking, equity research, institutional services, primary market research, asset management and corporate & venture services, and specializes in four growth industry sectors: CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. For more information, please go to http://www.mcfco.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at Canaccord Adams Global Growth Conference
2. Bionovo Reports Second Quarter 2008 Financial Results
3. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
4. Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds
5. Bionovo Reports First Quarter 2008 Financial Results
6. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
7. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
8. Louis Drapeau Joins Bionovos Board of Directors
9. George Butler Joins Bionovos Board of Directors
10. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
11. Bionovo Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017  Market Research Future published a half-cooked research ... expected to grow at a CAGR of 12% during the period ... ... to the abnormal cell division without any control. These abnormal cells ... them. These cancer cells can spread to other parts of the ...
(Date:1/17/2017)... Jan. 17, 2017  An international team of ... and St. Boniface Hospital Albrechtsen Research Centre/University of ... an unmet health need affecting nearly one in ... Clinical Investigation, their results identify small molecule drugs ... reverse neuronal injury in animal models of metabolic, ...
(Date:1/17/2017)... , Jan. 17, 2017 ... coaching, is the first to offer fully Spanish ... Noom,s Spanish diabetes prevention and ... reach and accessibility of lifestyle interventions among Hispanic ... these conditions. Noom,s robust food database, program-specific curriculum ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... at the 2016 annual meeting of the North American Spine Society (NASS)1 ... patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is used ...
Breaking Biology Technology:
(Date:12/8/2016)... PUNE, India , Dec. 8, 2016 Market Research ... and Service Market. The global Mobile Biometric Security and Service Market ... period 2016 to 2022. Market Highlights: ... , , ... fast pace due to the increasing need of authentication and security ...
(Date:12/7/2016)... 7, 2016 According to a new market research report ... (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region - Global ... from USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at ... Continue Reading ... MarketsandMarkets Logo ...
(Date:12/7/2016)...   Avanade is helping Williams Martini Racing, ... history, exploit biometric data in order to critically analyse ... competitive edge against their rivals after their impressive, record-breaking ... has worked with Williams during the 2016 season to ... rate, breathing rate, temperature and peak acceleration) for key ...
Breaking Biology News(10 mins):